03 Dec 2013 | 08:55 am |
We can confirm that David Rennick will be engaged by Pinsent Masons as a consultant early next year.
We have made excellent progress towards achieving our vision of becoming a law firm of truly international reach, and as part of that programme of growth are giving careful consideration to how we can capitalise on opportunities in the Australian market and in particular the strong linkages to our substantial Asia business and clients based around our offices in Singapore, Hong Kong, Shanghai and Beijing. David is a senior, well-respected figure in the region, well known to many of us, and his role on joining us will be to assist the senior management of the firm in evaluating the opportunities and make recommendations to the firm's partnership accordingly. It would be premature to speculate at this stage about what the outcome of that review might be.
Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.
Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.
Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]